At the heart of the COVID‐19 crisis: Perceived concerns of changes in long‐term cancer care in French women with cancer

Vecchia, Claire Della; Girodet, Magali; Ginguené, Stéphéline; Carpentier, Camille; Leroy, T.; Siméone, Arnaud; Vayre, Émilie; Mabire, Xavier; Ferraz, Dulce; Morin‐Messabel, Christine; Préau, Marie

doi:10.1111/ecc.13599

Cited by 5 publications

(2 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…d. Number and type of drug-drug interactions related to OAA. 26 e. Patient health locus of control according to the Therapeutic Self-Care measure. 27 4.…”

Section: Secondary Outcomes 1 Evaluation Of Oaa Management Consequencesmentioning

confidence: 99%

Cost-effectiveness of the ONCORAL multidisciplinary programme for the management of outpatients taking oral anticancer agents at risk of drug-related event: protocol for a pragmatic randomised controlled study

Huot,

Guerre,

Descotes

et al. 2024

BMJ Open

View full text Add to dashboard Cite

IntroductionThe development of oral anticancer agents (OAA) has profoundly changed cancer care, leading patients to manage their chemotherapy treatment on an outpatient basis. The prevention of iatrogenic effects of OAA remains a major concern, especially since their side effects are not less serious than those of intravenous chemotherapy. The ONCORAL programme was set up to secure the management of OAA in cancer patients followed at the Lyon University Hospital. This multidisciplinary programme involves hospital pharmacists, nurses, oncologists, and haematologists, as well as community health professionals. Given the economic stakes that this programme entails for the health system, a medico-economic study was designed.Methods and analysisThis is a prospective controlled study, with individual open-label randomisation. A total of 216 outpatients treated with OAA and at risk of developing a drug-related iatrogenic event, will be randomised (2:1) to undergo follow-up in the ONCORAL programme or usual care. The primary outcome will be the estimation of the incremental cost-effectiveness ratio (difference in total costs per quality adjusted life years gained) at 12 months between the two groups. The secondary outcomes will be evaluation of OAA management consequences (relative-dose intensity, adherence, adverse drug events, drug–drug interactions, and proven medication errors), evaluation of overall survival and cancer-related quality of life, and patient-reported outcomes in relation to the treatment. A budget impact analysis will be implemented. Patient and health professional satisfaction regarding the ONCORAL programme will be measured.Ethics and disseminationApproval to conduct this study was obtained from an Ethics Committee (Comité de Protection des Personnes Ile-de-France VI) in October 2019, and from the French data protection agency (Commission Nationale de l’Informatique et des Libertés), according to the French Law. Trial results will be disseminated at clinical conferences and published in peer-reviewed journals.Trial registrationNCT03660670.

show abstract

“…d. Number and type of drug-drug interactions related to OAA. 26 e. Patient health locus of control according to the Therapeutic Self-Care measure. 27 4.…”

Section: Secondary Outcomes 1 Evaluation Of Oaa Management Consequencesmentioning

confidence: 99%

Cost-effectiveness of the ONCORAL multidisciplinary programme for the management of outpatients taking oral anticancer agents at risk of drug-related event: protocol for a pragmatic randomised controlled study

Huot,

Guerre,

Descotes

et al. 2024

BMJ Open

View full text Add to dashboard Cite

show abstract

“…This group merits further research attention. Finally, it will also be necessary to integrate the patient perspectives of these innovations to understand how they will change their long-term cancer care [ 34 ].…”

Section: Limitationsmentioning

confidence: 99%

What went right during the COVID crisis: The capabilities of local actors and lasting innovations in oncology care and research

Bogaert,

Kozlakidis,

Caboux

et al. 2023

PLOS Glob Public Health

View full text Add to dashboard Cite

This article will elaborate how oncology care and research was adapted during the COVID pandemic in the Metropole of Lyon (France), including the lasting innovations that came out of the crisis. The research method involved 22 semi-structured qualitative interviews of healthcare professionals, managers, and researchers in the Lyon, France region coming from both public and private academic hospitals. The interviews took place from February 2021-December 2022 in order to assess the long-term adaptations and innovations in cancer care organization in the post-COVID era. The main results show adaptations and innovations in 1) new processes and resources to facilitate disciplinary and interdisciplinary work; 2) harmonization and streamlining of patient journeys. In the discussion section, we will mobilize the capabilities approach, an interdisciplinary social sciences approach that focuses on the capabilities of persons to be and to do, to elaborate the conditions by which local actors were able to be agile, to adapt and to innovate in spite of the healthcare emergency and in coherence with their professional and personal values.

show abstract

Measuring reconceptualization and reprioritization during France’s first COVID-19-related lockdown in women with and without a history of cancer: an adaptation of the SeiQol-DW and PGI

Bauquier,

Ginguené,

Leroy

et al. 2024

Qual Life Res

View full text Add to dashboard Cite

At the heart of the COVID‐19 crisis: Perceived concerns of changes in long‐term cancer care in French women with cancer

Cited by 5 publications

References 47 publications

Cost-effectiveness of the ONCORAL multidisciplinary programme for the management of outpatients taking oral anticancer agents at risk of drug-related event: protocol for a pragmatic randomised controlled study

Cost-effectiveness of the ONCORAL multidisciplinary programme for the management of outpatients taking oral anticancer agents at risk of drug-related event: protocol for a pragmatic randomised controlled study

What went right during the COVID crisis: The capabilities of local actors and lasting innovations in oncology care and research

Measuring reconceptualization and reprioritization during France’s first COVID-19-related lockdown in women with and without a history of cancer: an adaptation of the SeiQol-DW and PGI

Contact Info

Product

Resources

About